ASX healthcare stock Saluda Medical Inc (ASX: SLD) has been drawing significant attention from brokers in recent weeks. 

The growth stock is a commercial-stage medical device company. It is focused on developing treatments for chronic neurological conditions using its novel neuromodulation platform. 

The company’s first product, the Evoke System, is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain, and leg pain, and is designed to treat chronic neuropathic pain by providing spinal cord stimulation (SCS) therapy.

It hasn’t been smooth sailing for this ASX healthcare stock in recent times. Its share price has tumbled 71% year to date. 

However, Morgans sees major upside over the next 12 months. 

Here’s the latest from the broker. 

Solid FY26 for ASX healthcare stock

In a note out of Morgans this week, the broker said FY26 finished strong and mostly ahead of prospectus, but the more important development is showing greater visibility on the path to operating leverage. 

FY27 guidance calls for 25% to 35% revenue growth, 50% to 52% gross margin, and a US$95 to $101 million adjusted EBITDA loss, with management expecting 90% of incremental gross profit to translate into adjusted EBITDA improvement. 

Salesforce maturation is key, with 161 US reps at FY26 year-end, 55% fully trained and the majority of the remaining cohort expected to come online in 1HFY27. Growth looks set to come from higher productivity rather than simply adding headcount, with c30% of territories operating below a 40% fully loaded rep-cost/revenue threshold, providing evidence that the territory economics can work. 

We see FY27 as the first meaningful test of the model’s scalability, with higher physician utilisation, maturing territories and the CAP24 paddle lead providing potential upside to guidance. We adjust FY27-28 forecasts, with our DCF-based target price moving to A$2.17 (from A$2.94). SPECULATIVE BUY maintained.

This ASX healthcare stock closed trading yesterday at just over 41 cents per share. 

The target from Morgans indicates an upside potential of 422%. 

Other brokers also bullish

Morgans isn’t alone in its outlook for this ASX healthcare stock. 

The team at Bell Potter recently updated their price target to $1.60. 

This indicates an upside of over 285%. 

Speaking on the lofty target, the broker said: 

SLD’s US commercial execution continues to impress and accelerated considerably in recent quarters (34% US growth in Q3, 45% in Q4). Tailwinds continue to build following FDA approval of SLD’s paddle lead in June and ~40% of the current sales force expected to complete training in FY27 and contribute to revenue generation. Real-world data continues to affirm Evoke’s value proposition: greater efficacy durability means fewer reprogramming requirements and therefore greater revenue/rep compared to conventional devices.

The post Could this ASX healthcare stock really be set to rise 400%? Morgans thinks so  appeared first on The Motley Fool Australia.

More reading

• Bell Potter says this ASX healthcare share could rise 200%+

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The S&P/ASX 200 Index (ASX: XJO) has gained 3.2% over 12 months, but this ASX 200 gold stock has left those gains wanting.

The surging gold miner in question is Greatland Resources Ltd (ASX: GGP).

In late-afternoon trade on Thursday, Greatland Resources shares were trading for $11.33 apiece. That sees the share price up a whopping 83.1% since this time last year. And it gives the Aussie gold miner a market cap of just over $7.6 billion.

Greatland has benefited from both the strong gold price and the fast-rising copper price, with exposure to both through its Telfer and Havieron gold-copper mines in Western Australia.

And the ASX 200 gold stock has hardly been sitting idle.

Here’s why it still looks like a compelling buy today.

Why this ASX 200 gold stock could keep charging higher

MPC Markets’ Jonathan Tacadena recently analysed the outlook for Greatland’s surging shares (courtesy of The Bull).

“GGP is a gold and copper producer,” he noted.

Citing the first reason he issued a buy recommendation on the ASX 200 gold stock, Tacadena said, “The company produced 329,000 ounces of gold in full year 2026, comfortably beating guidance.”

And Greatland is keeping a lid on its production costs.

“All in sustaining costs [AISC] were also below guidance,” Tacadena said.

For FY 2026, Greatland Resources reported an AISC of $2,179 per ounce of gold produced.

Then there’s the miner’s admirable balance sheet.

“It held cash of $1.289 billion at June 30 and had no debt,” Tacadena noted.

As for the fourth reason the ASX 200 gold stock still looks like a good buy today, he concluded:

It has full upside exposure to the gold price via put options. A reserve upgrade at the Telfer mine in Western Australia is also encouraging. The company is enjoying favourable momentum.

What’s the latest from Greatland Resources?

Greatland Resources announced its FY 2026 results on 27 August, the first full year that it owned the Telfer gold mine.

The company reported revenue of $2.26 billion from sales of 326,859 ounces of gold and 14,730 tonnes of copper, with free cash flow of $737 million, soaring 413% from FY 2025.

On the bottom line, the ASX 200 gold stock achieved a net profit after tax (NPAT) of $862 million, up 156% year on year.

Commenting on the strong results, Greatland managing director Shaun Day said:

Our first full financial year of Telfer under our ownership delivered exceptional operating results, driven by significant productivity improvements in our open pit and underground mines, and an excellent performance in our processing operations.

The post Up 83%! 4 reasons I’d still buy this $8 billion ASX 200 gold stock today appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Greatland Resources, PEXA Group, Origin shares
• Greatland Resources shares fall despite profit and revenue surge on first full year of Telfer operation
• Macmahon Holdings awarded $485m Telfer contract extension
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Wesfarmers Ltd (ASX: WES) shares may be one of the most underrated dividend picks in the ASX blue-chip space.

It’s normally names like BHP Group Ltd (ASX: BHP) and Commonwealth Bak of Australia (ASX: CBA) that get a lot of the attention from income investors. But, the owner of Bunnings, Kmart, Officeworks, Priceline and several other businesses could be an even better choice.

If an investor put $4,000 to work in Wesfarmers shares, they could unlock a pleasing amount of passive income. Let’s look at the projection for the business and whether it’s an attractive opportunity.

Dividend projection for FY27

Wesfarmers has been steadily increasing its payout for shareholders in the last several years.

In the 2027 financial year, the business announced it would hike its annual dividend by 7.8% to $2.22 following an 8.3% rise of underlying earnings per share (EPS) to $2.534.

Analysts now expect the business can grow its annual dividend in FY27 as well. According to the projection on Commsec, the operator of Bunnings and Kmart could pay an annual dividend per share of $2.34. This would represent a year-over-year increase of 5.4%

At the time of writing, the potential payout of $2.34 per share in the 2027 financial year could translate into a dividend yield of 3% excluding franking credits and 4.3% including franking credits. That’s not the biggest dividend yield on the ASX, but it has become significantly more attractive after the 15% decline of the Wesfarmers share price in the last month.

What a $4,000 investment would do in Wesfarmers shares

At the time of writing, if an investor put $4,000 into Wesfarmers, they’d be able to buy 52 Wesfarmers shares.

Based on the dividend projections, an investor with 52 Wesfarmers shares could unlock $121.68 in dividend cash and $173.83 in grossed-up dividend income, including franking credits.

Is this a good time to invest in Wesfarmers shares?

The company had a solid FY26, with high single-digit underlying EPS growth. Both Kmart and Bunnings delivered mid-single-digit earnings growth during the year, and management reported ongoing solid sales growth for both businesses in the first few weeks of FY27.

Let’s look at Wesfarmers’ appeal to analysts. According to CMC Invest, there have been 11 analyst ratings on the business within the last three months. Two were a buy, three were a hold, and six were a sell.

The average price target from those 11 analysts is $78.46, implying a possible 2% rise over the next year.

That may not be a very compelling return on offer to some investors, so there could be even better ASX shares to consider.

The post If I buy $4,000 of Wesfarmers shares, how much dividend income will I receive? appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Flight Centre, Qantas, and Wesfarmers shares
• How much is needed in superannuation to target a $60,000 annual passive income?
• Buy, hold, sell: NAB, PLS Group, Wesfarmers shares
• Down 15%: Is it a good time to buy Wesfarmers shares?
• Don’t panic if these 9 ASX 200 shares fall today

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Wesfarmers. The Motley Fool Australia has recommended BHP Group and Wesfarmers. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.